CSI Market
Sign In | Register

Ligand Pharmaceuticals Incorporated (LGND) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LGND Annual Cash Flow →
Cash flow patterns shown here provide context for understanding Ligand Pharmaceuticals Incorporated's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income35.16
Depreciation & amortization16.43
Amortization of Other Assets1.63
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories1.14
Research and Development in Process0.00
Gain (Loss) on Disposition of Other Assets0.00
Share-based Compensation24.25
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax-
Non Cash Change In Estimated Fair Value Of Contingent Value Rights0.62
Prepayment License Revenuein Stockin Lieu of Cash-
Noncash Upfront Fee-
Convertible Notes Receivable Fair Value Period Increase Decrease-
Increase Decreasein Fair Value of Convertible Debt Receivable-
Stock Issued During Period Value Acquisitions-
Non Cash Milestone-
Deconsolidation Gain Or Loss Amount-
Stock Issued-
Unsettled Repurchase of Common Stock-
Equity Receivedin Repayment of Note Receivable-
Increase Decreasein Fair Value of Convertible Debt Receivable and Warrant-
Royalties Recorded Upon Adoption Of New Accounting Pronouncement-
Change In Derivative Asset And Liability Fair Value-
Restricted Cash Current-
Amortization Of Commercial License And Other Economic Rights-
Increase Decrease In Contract With Customer Liability-
Increase Decrease In Contract With Customer Liability-
Income taxes0.00
Losses/ -gains on Investments net15.62
Accounts Receivable6.92
Increase (Decrease) in Accounts Payable and Accrued Liabilities5.96
Increase (Decrease) in Interest Payable, Net0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Deferred Income Taxes0.55
Other Working Capital-0.98
Other Noncash Income (Expense)0.00
Other net2.70
Payments for (Proceeds from) Other Operating Activities-36.67
Discontinued operations0.00
Net Cash flow from Operating Activities72.71
Investing Activities
Capital Expenditures-0.25
Sale of Capital Items0.00
Short-term Investments Proceeds223.04
Short-term Investments Acq.0.00
Proceeds from Derivative Instrument, Investing Activities-1.63
Payments To Contingent Value Right Holders-
Purchases Of Property And Equipment And Building-
Proceeds from Repayment of Commercial License Rights-
Payments To Contingent Value Right Holders And Other Contingency Payments Investing Activity-
Purchase for Commercial License Rights-
Proceeds From Commercial License Rights-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments-1.25
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Business Two, Net of Cash Acquired0.00
Payments to Acquire Equity Method Investments0.00
Cash Divested from Deconsolidation0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net6.85
Discontinued operations0.00
Net Cash Flow from Investing Activities226.77
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-215.97
Long-term debt - borrowings700.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-43.75
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock114.10
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-22.08
Other net-0.01
Payments for Convertible Bond Hedges-
Purchase Of Convertible Bond Hedge-
Payments To Contingent Value Right Holders Financing Activity-
Finance Lease Principal Payments-0.01
Payments For Separation-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities532.30
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow72.46
Total Cash Flow831.78
4 historic quarters locked

Sign in to unlock the full Ligand Pharmaceuticals Incorporated cash flow history.

Sign In Create Free Account

About Ligand Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000886163-26-000044

Figures are derived from filed reports and may be restated. Historical data is subject to revision.